Alpha v beta 5 Integrin Antagonist for Sepsis Vascular Permeability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for sepsis are ineffective in targeting specific therapeutic mechanisms, and the molecular mechanisms underlying sepsis remain poorly understood, leading to high mortality rates despite clinical trials.
Innovation Solution
Administering an antagonist specific to the αvβ5 integrin, such as antibodies or small molecule inhibitors, to block the activity or expression of αvβ5 integrin, thereby reducing vascular permeability and alleviating sepsis symptoms, while avoiding interference with αvβ3 integrin to prevent adverse effects.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If general anti-inflammatory treatments are administered, then inflammation is reduced, but specificity is lost and effectiveness decreases
Solution Approach 1:
The patent segments the integrin family into distinct functional groups by targeting αvβ5 specifically, separating it from αvβ3 and other integrins. This segmentation allows selective inhibition of the pathogenic αvβ5 integrin while preserving the functions of other integrins, thereby improving treatment effectiveness without causing off-target effects.
Solution Approach 2:
The patent applies local quality by creating a highly specific antagonist that targets only αvβ5 integrin with distinct molecular recognition. The antibody or small molecule inhibitor is designed to bind specifically to epitopes or binding sites unique to αvβ5, providing localized and precise therapeutic action at the molecular level while leaving other integrins unaffected.
2Object-affected harmful factors
If broad-spectrum integrin inhibitors are used, then multiple integrin pathways are blocked, but specificity is lost and adverse effects increase
Solution Approach 1:
The patent introduces a highly specific intermediary molecule (antibody or small molecule inhibitor) that acts as a selective mediator between the therapeutic agent and the αvβ5 integrin. This intermediary provides precise molecular recognition and binding, blocking the pathogenic interaction between αvβ5 and its ligands (such as vitronectin or fibronectin) without interfering with other integrin-ligand interactions, thereby eliminating off-target effects.
3Reliability
If current sepsis therapies are administered, then general supportive care is provided, but mortality remains high due to lack of specific targets
Solution Approach 1:
The patent performs preliminary action by identifying and characterizing the specific role of αvβ5 integrin in sepsis pathogenesis before developing targeted therapies. Through in vitro and in vivo studies, the patent establishes the causal relationship between αvβ5-mediated endothelial barrier disruption and sepsis severity, providing a solid molecular foundation for subsequent targeted interventions and improving survival rates.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The targeted inhibition of αvβ5 integrin reduces the severity and mortality associated with sepsis, as demonstrated by increased survival rates in animal models, with αvβ5 antagonists specifically prolonging survival and reducing vascular permeability without affecting αvβ3 functions.
Implementation Method 1
an antagonist that specifically binds to αvβ5 integrin and blocks binding of a ligand to the integrin
Data Source
AI summary
The present invention provides compositions and methods for treating and preventing disease associated with αvβ5 integrin by blocking binding to αvβ5 integrin. In particular, antibodies specific for αvβ5 integrin are useful for preventing, treating, and reversing sepsis.